虞先濬 - 复旦大学 - 肿瘤研究所

个人简介

复旦大学附属肿瘤医院副院长，上海市胰腺肿瘤研究所所长，复旦大学胰腺肿瘤研究所所长，中国抗癌协会胰腺癌专业委员会候任主任委员，CSPAC中国胰腺癌多学科协作组组长，中华医学会外科学分会胰腺外科学组委员，中国医师协会胰腺病学专业委员会、中国临床肿瘤学会（CSCO）胰腺癌专家委员会常务委员，香港中文大学研究生院External Examiner，美国外科医师学院Fellow（FACS），Cancer Letters中国上海编辑部执行主任，Cancer Letters编委等多本国际著名杂志编委/特约审稿专家。　　长期致力于胰腺癌临床-基础转化研究，针对如何提升胰腺癌外科综合治疗水平，进而提高患者的长期生存这一问题，开展了系统的、逐步递进的应用基础和转化医学研究。获得国家自然科学基金委杰出青年基金，入选国家科技部中青年科技创新领军人才，上海市领军人才和上海市优秀学术/技术带头人计划，曾获得国际胰腺病学会Outstanding Achievement in Pancreatology大奖，上海工匠、上海市五一劳动奖章获得者。既往主持国家自然基金中德国际合作项目1项、面上项目3项，省部级项目12项；近5年以通讯作者(含共同)在J Clin Oncol、Gut、Ann Surg、Cell Res、Clin Cancer Res、Cancer Res等权威/主流期刊发表SCI论文150余篇，总IF＞500分，单篇论著最高IF：28.2分。作为第一发明人获得5项国家实用新型专利、上海市优秀发明选拔赛“金奖”。研究成果受到国内外同行认可，已被纳入多部国际、国内胰腺肿瘤临床指南/共识，指导临床实践。

研究领域

1.发明“胰肠吻合”新方法，减少胰瘘，提高了手术安全性 2.发明 5 项专用手术器械，协助深部淋巴结锐性清扫，使局部复发率降低 30%，提高了手术根治性 3.发现胰腺癌“手术不获益”亚群，施行术前个体化干预，提高了手术有效性 4.首次提出基于间质比例的胰腺癌个体化化疗策略，指导临床实践 5.发现胰腺恶性肿瘤增殖转移特性，两次创新改良国际临床分期指南，发出“中国好声音”

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Liang C., Shi S., Qin Y., Meng Q., Hua J., Hu Q., Ji S., Zhang B., Xu J., Yu X. J.* Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. Gut, 2019. Liang C., Xu J., Meng Q., Zhang B., Liu J., Hua J., Zhang Y., Shi S.*, Yu X.* TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status. Autophagy, 2019; 1-15. Shi S., Hua J., Liang C., Meng Q., Liang D., Xu J., Ni Q., Yu X*. Proposed Modification of the 8th Edition of the AJCC Staging System for Pancreatic Ductal Adenocarcinoma. Ann Surg, 2019; 269(5): 944-950. Zhang Y., Xu J., Hua J., Liu J., Liang C., Meng Q., Wei M., Zhang B., Yu X.*, Shi S*. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. J Immunother Cancer, 2019; 7(1): 233. Liang C., Shi S., Liu M., Qin Y., Meng Q., Hua J., Ji S., Zhang Y., Yang J., Xu J., Ni Q., Li M.*, Yu X*. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells. Cancer Res, 2019; 79(1): 133-145. Shi S., Liang C., Xu J., Meng Q., Hua J., Yang X., Ni Q., Yu X*. The Strain Ratio as Obtained by Endoscopic Ultrasonography Elastography Correlates With the Stroma Proportion and the Prognosis of Local Pancreatic Cancer. Ann Surg, 2018. Meng Q., Shi S., Liang C., Liang D., Hua J., Zhang B., Xu J., Yu X*. Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3beta/Snail signaling. Oncogene, 2018; 37(44): 5843-5857. Luo G., Liu C., Guo M., Cheng H., Lu Y., Jin K., Liu L., Long J., Xu J., Lu R., Ni Q., Yu X*. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. Ann Surg, 2017; 265(4): 800-805. Luo G., Javed A., Strosberg J. R., Jin K., Zhang Y., Liu C., Xu J., Soares K., Weiss M. J., Zheng L., Wolfgang C. L., Cives M., Wong J., Wang W., Sun J., Shao C., Wang W., Tan H., Li J., Ni Q., Shen L., Chen M., He J., Chen J.*, Yu X.* Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. J Clin Oncol, 2017; 35(3): 274-280. Ji S., Qin Y., Liang C., Huang R., Shi S., Liu J., Jin K., Liang D., Xu W., Zhang B., Liu L., Liu C., Xu J., Ni Q., Chiao P. J., Li M., Yu X*. FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer. Clin Cancer Res, 2016 Aug 1; 22(15): 3950-60. Wang W. Q., Liu L., Xu H. X., Wu C. T., Xiang J. F., Xu J., Liu C., Long J., Ni Q. X., Yu X. J*. Intratumoral infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma. Br J Surg, 2016. Ji S., Qin Y., Shi S., Liu X., Hu H., Zhou H., Gao J., Zhang B., Xu W., Liu J., Liang D., Liu L., Liu C., Long J., Zhou H., Chiao P. J., Xu J., Ni Q., Gao D., Yu X*. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res, 2015; 25(5): 561-573. Yao W., Ji S., Qin Y., Yang J., Xu J., Zhang B., Xu W., Liu J., Shi S., Liu L., Liu C., Long J., Ni Q., Li M., Yu X*. Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1alpha axis. Mol Cancer, 2014; 13187. Xu H. X., Chen T., Wang W. Q., Wu C. T., Liu C., Long J., Xu J., Zhang Y. J., Chen R. H., Liu L., Yu X. J*. Metabolic tumour burden assessed by (1)(8)F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging, 2014; 41(6): 1093-1102. Liu L., Xu H. X., Wang W. Q., Wu C. T., Chen T., Qin Y., Liu C., Xu J., Long J., Zhang B., Xu Y. F., Ni Q. X., Li M., Yu X. J*. Cavin-1 is essential for the tumor-promoting effect of caveolin-1 and enhances its prognostic potency in pancreatic cancer. Oncogene, 2014; 33(21): 2728-2736.